Business Practice

In the highly regulated precision medicine development sector, the agility and expertise of a CDMO can make or break a commercial drug candidate.

Donald Trump threatens “major tariff” on pharmaceuticals.

Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track

Thoughts on the US National Institutes of Health and its role in funding research for non-opioid therapeutics.

With competition for skilled employees in cell and gene therapy manufacturing high, companies need to invest in training and mentorship.

FDA letter sent to Edenbridge Pharmaceuticals demonstrates the challenges of getting pharma advertising right.

From geopolitical conflicts to cyber threats, CDMOs must rethink resilience.

In part 2 of our roundtable discussion, thought leaders discuss what Trump could do for drug pricing and whether change is to be feared or embraced.

Biden pushed drug pricing reforms, whereas Trump is known for deregulation. What does this mean for pharma?

Bluebird bio’s financial situation is a stark reminder of the challenges of developing advanced therapies for rare diseases.